Pressemitteilungen
![](https://www.janssen.com/germany/sites/www_janssen_com_germany/files/styles/medium/public/jc_websitenews_artikel_nominierung_janssenaward_210120.jpg?itok=fujLGfqZ)
26. Januar 2021
Nominierung Dr. Paul Janssen Award
![](https://www.janssen.com/germany/sites/www_janssen_com_germany/files/styles/medium/public/images/block_images/jc_atm_report_websitenews_artikel.jpg?itok=foK3cYYR)
26. Januar 2021
Johnson & Johnson auf Platz 3 im Access to Medicine Index ATMI
![Hardenbicker Interview Healthcare Marketing](https://www.janssen.com/germany/sites/www_janssen_com_germany/files/styles/medium/public/hardenbicker_375x280px.jpg?itok=e1iqKU4L)
21. Dezember 2020
Markus Hardenbicker im Interview
![](https://www.janssen.com/germany/sites/www_janssen_com_germany/files/styles/medium/public/images/block_images/blank_503x375px.png?itok=by9CGPcQ)
18. Dezember 2020
Janssens Covid-19-Impfstoffkandidat
![Hardenbicker Interview Healthcare Marketing](https://www.janssen.com/germany/sites/www_janssen_com_germany/files/styles/medium/public/hardenbicker_375x280px.jpg?itok=e1iqKU4L)
16. Dezember 2020
COVID-19 und digitales Arbeiten
![Logo von Yes!Con, Deutschlands erste digitale Krebs-Convention](https://www.janssen.com/germany/sites/www_janssen_com_germany/files/styles/medium/public/yescon375x280.png?itok=pFHjVMJv)